Tags

Type your tag names separated by a space and hit enter

Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study.
J Sex Med. 2012 Jan; 9(1):271-81.JS

Abstract

INTRODUCTION

Erectile dysfunction (ED) and lower urinary tract symptoms suggestive of benign prostatic hyperplasia (BPH-LUTS) commonly coexist in aging men. Tadalafil, a phosphodiesterase type 5 inhibitor approved for treating ED, is currently being evaluated for treating BPH-LUTS.

AIMS

This multinational Phase 3 study assessed effects of tadalafil 2.5 or 5 mg once daily on ED and BPH-LUTS in men with both conditions during 12 weeks of double-blinded therapy.

METHODS

Men were ≥ 45 years old, sexually active, and experiencing ED for ≥ 3 months and BPH-LUTS for >6 months. Randomization (baseline) followed a 4-week placebo lead-in; changes from baseline were assessed via analysis of covariance and compared to placebo. A gatekeeping procedure controlled for multiple comparisons of co-primary and key secondary measures at end point (last post-baseline observation).

MAIN OUTCOME MEASURES

The co-primary measures were the International Index of Erectile Function-erectile function (IIEF-EF) domain and International Prostate Symptom Score (IPSS) score; key secondary measures were the Sexual Encounter Profile Question 3 (SEP Q3) and BPH Impact Index (BII). Treatment-emergent adverse events, serious adverse events, orthostatic vital signs, clinical laboratory and uroflowmetry parameters, and postvoid residual volume were assessed.

RESULTS

Tadalafil 2.5 mg (N = 198) and 5 mg (N = 208) significantly improved IIEF-EF domain scores (both P < 0.001) vs. placebo (N = 200) at end point. For IPSS, improvements were significant with tadalafil 5 mg (P < 0.001), but not 2.5 mg, for observations from 2 weeks through end point (least-squares mean ± standard error change from baseline at end point, placebo -3.8 ± 0.5, tadalafil 2.5 mg -4.6 ± 0.4, and 5 mg -6.1 ± 0.4). Tadalafil 5 mg significantly improved SEP Q3 and BII (P < 0.001). Overall, tadalafil was well tolerated with no clinically adverse changes in orthostatic vital signs or uroflowmetry parameters.

CONCLUSIONS

Tadalafil 5 mg significantly improved both ED and BPH-related outcomes through 12 weeks and was well tolerated.

Authors+Show Affiliations

Urology Associates/Urologic Medical Research, Kitchener, Canada. blairegerdie@mac.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial, Phase III
Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

21981682

Citation

Egerdie, Russell Blair, et al. "Tadalafil 2.5 or 5 Mg Administered once Daily for 12 Weeks in Men With Both Erectile Dysfunction and Signs and Symptoms of Benign Prostatic Hyperplasia: Results of a Randomized, Placebo-controlled, Double-blind Study." The Journal of Sexual Medicine, vol. 9, no. 1, 2012, pp. 271-81.
Egerdie RB, Auerbach S, Roehrborn CG, et al. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study. J Sex Med. 2012;9(1):271-81.
Egerdie, R. B., Auerbach, S., Roehrborn, C. G., Costa, P., Garza, M. S., Esler, A. L., Wong, D. G., & Secrest, R. J. (2012). Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study. The Journal of Sexual Medicine, 9(1), 271-81. https://doi.org/10.1111/j.1743-6109.2011.02504.x
Egerdie RB, et al. Tadalafil 2.5 or 5 Mg Administered once Daily for 12 Weeks in Men With Both Erectile Dysfunction and Signs and Symptoms of Benign Prostatic Hyperplasia: Results of a Randomized, Placebo-controlled, Double-blind Study. J Sex Med. 2012;9(1):271-81. PubMed PMID: 21981682.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study. AU - Egerdie,Russell Blair, AU - Auerbach,Stephen, AU - Roehrborn,Claus G, AU - Costa,Pierre, AU - Garza,Martin Sanchez, AU - Esler,Anne L, AU - Wong,David G, AU - Secrest,Roberta J, Y1 - 2011/10/07/ PY - 2011/10/11/entrez PY - 2011/10/11/pubmed PY - 2012/5/9/medline SP - 271 EP - 81 JF - The journal of sexual medicine JO - J Sex Med VL - 9 IS - 1 N2 - INTRODUCTION: Erectile dysfunction (ED) and lower urinary tract symptoms suggestive of benign prostatic hyperplasia (BPH-LUTS) commonly coexist in aging men. Tadalafil, a phosphodiesterase type 5 inhibitor approved for treating ED, is currently being evaluated for treating BPH-LUTS. AIMS: This multinational Phase 3 study assessed effects of tadalafil 2.5 or 5 mg once daily on ED and BPH-LUTS in men with both conditions during 12 weeks of double-blinded therapy. METHODS: Men were ≥ 45 years old, sexually active, and experiencing ED for ≥ 3 months and BPH-LUTS for >6 months. Randomization (baseline) followed a 4-week placebo lead-in; changes from baseline were assessed via analysis of covariance and compared to placebo. A gatekeeping procedure controlled for multiple comparisons of co-primary and key secondary measures at end point (last post-baseline observation). MAIN OUTCOME MEASURES: The co-primary measures were the International Index of Erectile Function-erectile function (IIEF-EF) domain and International Prostate Symptom Score (IPSS) score; key secondary measures were the Sexual Encounter Profile Question 3 (SEP Q3) and BPH Impact Index (BII). Treatment-emergent adverse events, serious adverse events, orthostatic vital signs, clinical laboratory and uroflowmetry parameters, and postvoid residual volume were assessed. RESULTS: Tadalafil 2.5 mg (N = 198) and 5 mg (N = 208) significantly improved IIEF-EF domain scores (both P < 0.001) vs. placebo (N = 200) at end point. For IPSS, improvements were significant with tadalafil 5 mg (P < 0.001), but not 2.5 mg, for observations from 2 weeks through end point (least-squares mean ± standard error change from baseline at end point, placebo -3.8 ± 0.5, tadalafil 2.5 mg -4.6 ± 0.4, and 5 mg -6.1 ± 0.4). Tadalafil 5 mg significantly improved SEP Q3 and BII (P < 0.001). Overall, tadalafil was well tolerated with no clinically adverse changes in orthostatic vital signs or uroflowmetry parameters. CONCLUSIONS: Tadalafil 5 mg significantly improved both ED and BPH-related outcomes through 12 weeks and was well tolerated. SN - 1743-6109 UR - https://www.unboundmedicine.com/medline/citation/21981682/Tadalafil_2_5_or_5_mg_administered_once_daily_for_12_weeks_in_men_with_both_erectile_dysfunction_and_signs_and_symptoms_of_benign_prostatic_hyperplasia:_results_of_a_randomized_placebo_controlled_double_blind_study_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1743-6095(15)33749-8 DB - PRIME DP - Unbound Medicine ER -